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ABSTRACT
Aims: To identify distinct asthma control clusters based on Control of Allergic Rhinitis and Asthma Test (CARAT) 
and to compare patients’ characteristics among these clusters. Methods: Adults and adolescents (≥13 years) with 
persistent asthma were recruited at 29 Portuguese hospital outpatient clinics, in the context of two observational 
studies of the INSPIRERS project. Demographic and clinical characteristics, adherence to inhaled medication, beliefs 
about inhaled medication, anxiety and depression, quality of life, and asthma control (CARAT, >24 good control) were 
collected. Hierarchical cluster analysis was performed using CARAT total score (CARAT -T). Results: 410 patients 
(68% adults), with a median (percentile 25–percentile 75) age of 28 (16 -46) years, were analysed. Three clusters were 
identified [mean CARAT -T (min -max)]: cluster 1 [27(24 -30)], cluster 2 [19(14 -23)] and cluster 3 [10(2 -13)]. Patients in 
cluster 1 (34%) were characterised by better asthma control, better quality of life, higher inhaler adherence and use 
of a single inhaler. Patients in clusters 2 (50%) and 3 (16%) had uncontrolled asthma, lower inhaler adherence, more 
symptoms of anxiety and depression and more than half had at least one exacerbation in the previous year. Further-
more, patients in cluster 3 were predominantly female, had more unscheduled medical visits and more anxiety symp-
toms, perceived a higher necessity of their prescribed inhalers but also higher levels of concern about taking these 
inhalers. There were no differences in age, body mass index, lung function, smoking status, hospital admissions or 
specialist physician follow -up time among the three clusters. Conclusion: An unsupervised method based on CARAT-
-T, identified 3 clusters of patients with distinct, clinically meaningful characteristics. The cluster with better asthma 
control had a cut -off similar to the established in the validation study of CARAT and an additional cut -off seems to 
distinguish more severe disease. Further research is necessary to validate the asthma control clusters identified.
Keywords: Asthma, asthma control, classification, cluster analysis, control of allergic rhinitis and asthma test.
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INTRODUCTION
Asthma is a common, chronic disease character-ised by airway inflammation1. The long -term goals of asthma management are to achieve 
good control of symptoms and minimise future risk of 
exacerbations1. However, large observational studies 
have shown that these goals are not being easily achieved, 
even in patients with mild disease2 -4.
Treatments can be very successful for some patients 
but not for others, leading to poor outcomes, unneces-
sary suffering and elevated direct and indirect costs5,6. 
This is mainly related to the heterogeneous nature of 
asthma1, supporting the existence of distinct asthma con-
trol profiles, which differ in their characteristics and treat-
ment responsiveness.
Unsupervised methods, particularly cluster analysis, 
have been used to identify subtypes of asthma with simi-
lar characteristics to predict future risks and/or to con-
tribute for the implementation of personalised thera-
pies7,8. However, most of the studies that identified 
asthma clusters were based on clinical and inflammatory 
biomarkers9 -12 of adult patients with moderate to severe 
asthma, preventing clusters’ generalization to younger 
and/or less severe patients and their implementation into 
real practice. Further studies that explore subtypes of 
asthma control using data easily obtained in clinical prac-
tice, such as questionnaire -based information, could un-
ravel the complex links underlying asthma control.
The Control of Allergic Rhinitis and Asthma Test 
(CARAT) is a self -administered questionnaire com-
monly used to assess asthma control both in clinical 
RESUMO
Objetivos: Identif icar clusters de controlo da asma baseados no Teste de Controlo da Asma e Rinite Alérgica (CARAT) e 
comparar as características dos doentes nos diferentes clusters. Métodos: Adultos e adolescentes (≥13 anos) com asma per-
sistente foram recrutados em 29 centros no contexto de 2 estudos observacionais do projeto INSPIRERS. Foram recolhidos 
dados relativos a características demográficas e clínicas, adesão ao inalador, crenças sobre a medicação, sintomas de ansieda-
de e depressão, qualidade de vida e controlo da asma (CARAT, >24 bom controlo). Foi efetuada uma análise hierárquica de 
clusters usando a pontuação total do CARAT (CARAT -T). Resultados: Foram analisados 410 doentes (68% adultos), com uma 
idade mediana (percentil 25–percentil 75) de 28 (16 -46) anos. Foram identif icados três clusters [média CARAT -T(min -max)]: 
cluster 1 [27(24 -30)], cluster 2 [19(14 -23)] e cluster 3 [10(2 -13)]. Os doentes no cluster 1 (34%) apresentavam melhor contro-
lo da asma, melhor qualidade de vida, maior adesão aos inaladores e usavam um único inalador. Os doentes nos clusters 2 
(50%) e 3 (16%) tinham a asma não controlada, menor adesão aos inaladores, mais sintomas de ansiedade e depressão e mais 
de metade reportavam pelo menos uma exacerbação no último ano. Adicionalmente, os doentes no cluster 3 eram predomi-
nantemente mulheres, tinham mais consultas médicas não agendadas, apresentavam mais sintomas de ansiedade, percebiam 
uma maior necessidade dos inaladores, mas também uma maior preocupação associada ao seu uso. Não se verif icaram dife-
renças na idade, índice de massa corporal, função pulmonar, hábitos tabágicos, hospitalizações ou tempo de seguimento pelo 
médico especialista. Conclusões: Um método não supervisionado baseado no CARAT -T, identif icou 3 clusters de doentes com 
diferentes características clínicas. O cluster com melhor controlo apresenta um ponto de corte semelhante ao estabelecido no 
estudo de validação do CARAT. Este estudo sugere ainda a existência de um ponto de corte adicional para distinguir doença 
mais grave. Mais investigação é necessária para validar os clusters identif icados.
Palavras -chave: Análise de clusters, asma, classificação, controlo da asma, teste de controlo da asma e rinite alérgica.
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studies and clinical practice13. It is composed of 10 ques-
tions that address upper and lower airway symptoms, 
sleep interference, activities limitation, and the need to 
increase medication over a 4 -week period. The total 
score (CARAT -T) is calculated by summing the score of 
each question, resulting in a range of 0–30 points. In the 
original validation study, a CARAT -T>24 was indicative 
of good disease control. This work also showed that 
CARAT -T can be used to compare groups and to evalua-
te individual patients over time. However, to date, the 
CARAT -T ability to identify asthma control clusters was 
not explored.
This preliminary study aimed to identify asthma con-
trol clusters based on CARAT -T in a cohort of Portuguese 
adolescents and adults with persistent asthma and to 




Two prospective observational studies of the INSPIR-
ERS project were analysed14,15 and data from initial face-
-to -face visit and 1 -week telephone interview were col-
lected. A convenience sample of patients with persistent 
asthma was recruited between November 2017 and June 
2018 at 29 allergy, pulmonology and paediatric secondary 
care outpatient clinics covering 6 Portugal regions (North, 
Center, Lisbon, Algarve, Azores, Madeira). The study 
protocols were approved by the ethics committees of all 
participating centres and by the national data protection 
committee. The study was conducted in accordance with 
the ethical standards established in the Declaration of 
Helsinki of 1946. Eligible patients were approached by 
physicians during medical visits and written informed 
consent was obtained before enrolment in the study. 
Adult patients signed a consent form; adolescents signed 
an assent form and a parental consent form was also 
obtained. The study is reported according to STROBE 
(Strengthening the Reporting of Observational Studies in 
Epidemiology) guidelines16.
Participants
Patients were included if they had a previous medical 
diagnosis of persistent asthma; were at least 13 years old 
(13 -17 years adolescents; ≥18 years adults); and had an 
active prescription for an inhaled controller medication 
for asthma. All inhaled controller treatments were al-
lowed and there was no change in any prescribed medica-
tion in relation to the participation in these studies. Pa-
tients were excluded if they had a diagnosis of a chronic 
lung disease other than asthma or a diagnosis of another 
significant chronic condition with possible interference 
with the study aims.
Data collection
During the initial face -to -face visit, data were col-
lected from both physicians and patients. Physicians 
answered a questionnaire including: assessment of pa-
tients’ asthma control according to the Global Initiative 
for Asthma (GINA)1; last known value of percent pre-
dicted Forced Expiratory Volume in first second (FEV1); 
number of exacerbations, defined as episodes of progres-
sive increase in shortness of breath, cough, wheezing, 
and/or chest tightness, requiring change in maintenance 
therapy 17; use of health care resources, namely number 
of unscheduled medical visits and number of hospital ad-
missions; and specialist follow -up time (measured in 
months). Physicians also reported the patients’ current 
asthma treatment, including inhaled medication, allergen 
immunotherapy and biologic therapy.
Demographic – age, gender, smoking habits – and 
anthropometric – height, weight – data were collected 
from patients, along with health information as described 
next. Asthma control in the patients’ perspective was 
assessed with CARAT13. The total score (CARAT -T) is 
calculated by summing the score of each of the 10 ques-
tions, resulting in a range of 0–30 points. A score >24 
indicates good disease control.
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The Portuguese version of the Hospital Anxiety and 
Depression Scale (HADS) was used to assess anxiety and 
depression symptoms18. The HADS contains 14 items, 
seven measuring anxiety symptoms (HADS -A) and seven 
depression symptoms (HADS -D), which are scored sepa-
rately. Each item has a 4 -point response category, so the 
possible scores range from 0 (minimum symptom load) 
to 21 (maximum symptom load) for HADS -A and for 
HADS -D. A score ≥8 in the HADS -A/HADS -D was used 
to consider the presence of clinically significant anxiety 
and depression symptoms18.
EQ -5D visual analogue scale (VAS) was used to assess 
health -related quality of life19,20. The VAS ranges from 0 
(worst imaginable health state) to 100 (best imaginable 
health state) millimetres. Patients assessed their global 
adherence to inhaled controller medication for asthma 
during the previous week also using a VAS, ranging from 
0 (worst) to 100 (best) millimetres21.
Approximately one week later14, through a telephone 
interview, patients were asked about their attitudes and 
beliefs in relation to their inhalers using the Portuguese 
version of the specific Beliefs about Medicines Question-
naire (BMQ -Specific)22. The BMQ -Specific is an 11 -item 
questionnaire that comprises two subscales: a 5 -item 
Necessity scale, to assess beliefs about the necessity for 
pres cribed medication (Specific -Necessity), and a 6 -item 
Concerns scale, to assess beliefs about the danger of 
dependence and long -term toxicity and the disruptive 
effects of medi cation (Specific -Concerns). Each item is 
scored on a 5 -point Likert scale (from 1 = strongly disa-
gree to 5 = strongly agree), and the total scores for the 
Necessity and Concerns subscales range from 5 to 25 
and from 6 to 30, respectively. The higher the score, the 
greater is the patient’s belief in the concept represented 
by the scale22.
Statistical Analysis
Descriptive statistics were used to characterise the 
sample. Normality of each variable was investigated 
with Kolmogorov -Smirnov Tests and visual analysis of 
histograms. To identify asthma control profiles based 
on CARAT -T, we conducted hierarchical cluster analy-
sis using a squared Euclidean distance measure to assess 
similarity/dissimilarity across variables, and between-
-groups linkage method for combining clusters. The 
Bayesian Information Criterion (BIC) was also calcu-
lated for the number of clusters obtained. To compare 
differen ces among clusters for continuous variables, 
one -way ANOVA (normally distributed) or Kruskal-
-Wallis test (not normally distributed) with Bonferroni 
correction were used. Chi -square tests were used for 
categorical variables. Statistical analyses were per-
formed using IBM SPSS Statistics version 25.0 (IBM 
Corporation, Armonk, NY, USA) and plots were crea-
ted using GraphPad Prism version 6.0 (GraphPad Soft-
ware, Inc., La Jolla, CA, USA). The level of significance 
was set at 0.05.
RESULTS
Participants
From the 413 patients included in both studies, 410 
had complete data on CARAT. Patients were mostly adults 
(68%) and female (61%). Characteristics of the participants 
are shown in Table 1.
Clusters of asthma control
Three clusters were identified as shown in Figure 1 
(BIC= 97.5). Cluster 2 was the largest cluster including 
half of the participants (n=204, 50%), followed by cluster 
1 (n=141, 34%) and cluster 3 (n=65, 16%).
Characteristics of each cluster are presented on Table 
2. Most patients in cluster 1 had their asthma controlled 
both using the CARAT cut -off or GINA classification. 
They were also characterized by higher inhaler adherence, 
use of a single inhaler (45% in a once -daily regimen), bet-
ter quality of life and equal gender distribution.
All patients in clusters 2 and 3 had uncontrolled asth-
ma using the CARAT cut -off and more than half had 
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partly controlled/uncontrolled asthma using GINA clas-
sification. Patients in clusters 2 and 3 had also lower in-
haler adherence, more than half had at least one exacer-
bation in the previous year and more symptoms of 
anxiety and depression.
Furthermore, patients in cluster 3 were predomi-
nantly female, had more unscheduled medical visits, pre-
sented more symptoms of anxiety, perceived a higher 
necessity of their prescribed inhalers but also higher 
levels of concern about taking these inhalers.
There were no significant differences in age, BMI, FEV1, 
smoking status, hospital admissions or specialist follow -up 
time among clusters.
DISCUSSION
To our knowledge, this is the first study using an un-
supervised method to identify subgroups of asthma con-
trol solely based on the total score of the self -reported 
questionnaire CARAT. We were able to identify 3 clusters 
of patients that differed in a number of characteristics 
such as adherence to inhaled medication, beliefs about 
inhaled medication, number of inhalers prescribed, num-
Table 1. Participants’ characteristics (n=410).
Total (n=410)
Age, median (P25 -P75), years 28 (16 -46)
Adults 280 (68%)
Female 249 (61%)

































Allergen immunotherapy 74 (18%)
Biologic therapy 25 (6%)
CARAT -T, mean (SD) 20.2 (6.3)
Values are shown as n (%) unless otherwise indicated.
BMI – body mass index; CARAT -T – Control of Allergic Rhinitis 
and Asthma Test total score; ICS – inhaled corticosteroids; 
LABA – long -acting beta -agonists; LAMA – long -acting 
muscarinic receptor antagonists; P25–P75 – percentile 25 to 
percentile 75; SABA – short -acting beta -agonists; SAMA – 
short -acting muscarinic -antagonists.
Figure 1. Clusters based on Control of Allergic Rhinitis and Asthma Test (CARAT) total score (CARAT 
mean, range)
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ber of exacerbations and unscheduled medical visits in 
the previous year, symptoms of anxiety and depression, 
health -related quality of life and gender distribution. The 
clusters found were not determined by any a priori clini-
cal knowledge, but rather on the total score of an asthma 
control self -reported questionnaire, easily applied in 
daily clinical practice.
From the distributions of CARAT -T across the 3 clus-
ters, it is possible to observe that two cut -offs (≥24 and 
≥14) emerged from the unsupervised analyses. The cut -off 
for controlled disease is in line with the cut -off suggested 
in the original validation study of CARAT (>24)23. The 
slight difference might be related with differences in the 
samples used. The validation study included a smaller 
sample of adults with asthma (n=62) recruited from 4 
allergy secondary care outpatient clinics in three Portu-
guese regions23; while in the present study a larger and 
more representative sample was used: adolescents were 
also included and patients were recruited by 3 medical 
specialities (allergy, pulmonology and paediatrics) from 6 













Age, median (P25 -P75) years 29 [16 -45] 26 [16 -46] 34.5 [16.3 -52.5] 0.251
Female 71 (50.4) 128 (62.7) 50 (76.9) 0.001 0.022 <0.001 0.035
BMI, median (P25 -P75) kg/m2 23.7 [20.8 -27] 23.7 [21.4 -27.3] 23.6 [20.9,28.7] 0.673


























Inhaler Adherence VAS, median (P25 -P75) 90 [76.8,98] 80 [65,95] 80 [54, 95] 0.005 0.005 0.007 0.506
Single inhaler 106 (75.2) 122 (59.8) 45 (69.2) 0.033 0.009 0.354 0.318
Necessity, median (P25 -P75) 19 [17, 21] 19 [16,22] 21 [18,23] 0.008 0.524 0.007 0.020
Concerns, median (P25 -P75) 15 [12, 17] 16 [12.8,19] 17 [14,21] 0.006 0.474 0.004 0.068
Controlled CARAT 119 (84.4) 0 0 <0.001 <0.001 <0.001  -
GINA assessment symptom control
 Well -controlled













<0.001 <0.001 <0.001 0.016
≥ 1 exacerbations past year 51 (36.2) 107 (52.5) 41 (63.1) <0.001 0.001 <0.001 0.101
Number unscheduled medical visits past year, 
median (P25 -P75)
0 [0,1] 1 [1,2] 1 [0.5,2.5] 0.020 0.329 0.015 0.253
≥ 1 hospital admissions past year 3 (2.1) 7 (3.4) 5 (7.7) 0.431
Anxiety symptoms 32 (22.7) 67 (32.8) 36 (55.4) <0.001 0.053 <0.001 0.002
Depression symptoms 7 (5) 27 (13.2) 16 (24.6) <0.001 0.016 <0.001 0.034
EQ -5D VAS, median (P25 -P75) 88.5 [80,91.1] 80 [70,90] 70 [55,80] <0.001 <0.001 <0.001 <0.001
Specialist follow up time ≥1 year 113 (80.1) 144 (70.6) 49 (75.4) 0.169
Values are shown as n (%) unless otherwise indicated. Significant values marked in bold.
BMI – body mass index; CARAT –Control of Allergic Rhinitis and Asthma Test; FEV1 – forced expiratory volume in one second; 
GINA – Global Initiative for Asthma; P25–P75 – percentile 25 to percentile 75; VAS – visual analogue scale.
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Portuguese regions. An additional CARAT cut -off of 14 
is for the first time proposed and seems to be able to 
distinguish patients with partly controlled disease and 
uncontrolled disease. This cut -off may be useful to clini-
cians to identify individuals with different risk levels and 
to individualize care in order to maximise outcomes. 
Nevertheless, this cut -off needs further validation before 
implementation into clinical practice.
Patients in the cluster with better asthma control had 
higher self -reported adherence to inhaled medication 
compared to patients from the other two clusters. Al-
though it is possible that all patients were overestimating 
real adherence24,25, this result suggests that asthma con-
trol is associated with adherence behaviours. In addition, 
most patients in this cluster had a single inhaler, and al-
most half in a once -daily regimen; possibly suggesting that 
simple therapeutic plans are related with better adher-
ence and asthma control26. A randomized control study 
with patients with asthma has previously shown that 
using a single inhaler for both maintenance treatment 
and symptom relief increased the dose of inhaled corti-
costeroid taken27. But evidence on the link between ad-
herence and number of drugs or daily doses is still in-
conclusive28. This may be related to the fact that there 
is no “gold standard” in evaluating adherence29. Patients 
in the cluster with worst asthma control perceived a 
higher necessity of their prescribed inhalers, but also 
higher levels of concern about taking these inhalers. In-
deed, more concerns about medication have been re-
lated to worse adherence28.
Patients from clusters 2 and 3, as expected, had more 
exacerbations than patients from cluster 1, as result of 
poor disease control. These patients had also poorer 
quality of life and more frequently depression. These 
characteristics have been previously found to distinguish 
asthma subtypes7,10,11. Patients in cluster 3 were in addi-
tion predominantly female, had more unscheduled med-
ical visits, presented more symptoms of anxiety. These 
characteristics are commonly present in patients with 
difficult to treat asthma or severe asthma30. In fact, this 
cluster includes 16% of the patients, which is in line with 
described prevalence of difficult -to -treat asthma (17%)31 
and severe asthma (3 -10%)31,32.
Strengths and limitations of this study should be rec-
ognized. The inclusion of adolescents with persistent 
asthma in our sample and the recruitment at 29 secondary 
healthcare centres are strengths of the present study. Yet 
patients were recruited by convenience sampling, which 
limits the generalizability of the results. Population studies 
with larger sample size and an extended age range (inclu-
ding children and older adults) and from other healthcare 
settings (e.g. primary care) should be conducted in future. 
Another strength of our study was the use of variables 
easily obtained in clinical practice. Patients’ allergic profile, 
treatment step and comorbidities (e.g., rhinitis) were not 
analysed but might also play a role in cluster differentiation. 
Future studies could address these issues in order to 
validate the three asthma control clusters identified or 
identify other types. These asthma control clusters were 
identified using a single clustering method – hierarchical 
cluster analysis and a single variable – CARAT -T. Although 
this is one of the most common clustering methods used 
in asthma8,10, future studies using CARAT -T and/or other 
self -reported variables could also use other unsupervised 
methods that shown to be promising in identifying clusters 
of subjects with allergic respiratory diseases, such as latent 
class or profile analysis33,34.
CONCLUSIONS
Using an unsupervised method based on CARAT -T, 
we identified 3 clusters of patients with distinct, clinically 
meaningful characteristics. The cluster with better asthma 
control generated by this unsupervised method had a cut-
-value similar to the established in the validation study of 
CARAT. An additional cut -off, that seems to distinguish 
more severe disease also emerged from this preliminary 
analysis. Further research is necessary to better cha racte-
rize the identified clusters of asthma control.
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